Maya Ramachandran, Jackson Voss, Jessica Ferrell, Jella Angela An
{"title":"MicroPulse®经巩膜激光治疗使用改进的MicroPulse P3®传送装置的结果","authors":"Maya Ramachandran, Jackson Voss, Jessica Ferrell, Jella Angela An","doi":"10.5005/jp-journals-10078-1460","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims and background: </strong>To evaluate the safety and efficacy of MicroPulse<sup>®</sup> transscleral laser therapy (MP-TLT) using the revised MicroPulse P3<sup>®</sup> (MP3) probe compared to the original probe.</p><p><strong>Materials and methods: </strong>A retrospective study of 122 consecutive eyes of 99 glaucoma patients who received MP-TLT with a minimum of 12 months follow-up. The primary outcome was success at 12 months, defined as final IOP <18 mm Hg and either IOP reduction of >20% or any medication reduction, without any adverse events or secondary surgical interventions (SSIs) within 12 months.</p><p><strong>Results: </strong>Ninety-five eyes in 75 patients were treated with the original probe, and 27 eyes of 24 patients were treated with the revised probe. The mean total energy and fluence used were 113.6 joules (J) and 54.3 J/cm<sup>2</sup> for the original probe, and 79.9 J and 140.1 J/cm<sup>2</sup> for the revised probe. Subjects were mostly white with primary open-angle glaucoma and a mean age of 70.3 years. Significantly more eyes with advanced glaucoma were treated with the revised probe compared to the original probe (<i>p</i> < 0.001). At baseline, mean IOP was 23.0 ± 7.5 on 2.94 ± 1.19 medications for the original probe compared to 22.6 ± 6.9 (<i>p</i> = 0.799) on 3.15 ± 1.32 medications (<i>p</i> = 0.429) for the revised probe. At 12 months, mean IOP was 17.9 ± 5.9 mm Hg (21.4% reduction) on 2.55 ± 1.40 medications (13.0% reduction) for the original probe compared to 14.8 ± 5.7 mm Hg (29.7% reduction, <i>p</i> = 0.063) on 3.07 ± 1.49 medications (2.2% reduction, <i>p</i> = 0.279) for the revised probe. Thirty-one of 95 eyes (32.6%) and 11 of 27 eyes (40.7%) treated with original and revised MP-TLT, respectively, achieved success at 12 months (<i>p</i> = 0.435). The rate of SSIs was 12% and similar between groups (<i>p</i> = 0.833). Significantly more eyes treated with the original probe underwent repeat MP-TLT within 12 months (44.2 vs 22.2%, <i>p</i> = 0.049). No adverse events occurred in either group.</p><p><strong>Conclusion and clinical significance: </strong>The revised probe for the MP3 device may result in an improved and longer-lasting IOP-lowering effect compared to the original probe, while maintaining an excellent safety profile.</p><p><strong>How to cite this article: </strong>Ramachandran M, Voss J, Ferrell J, <i>et al</i>. Outcomes of MicroPulse<sup>®</sup> Transscleral Laser Therapy Using the Revised MicroPulse P3<sup>®</sup> Delivery Device. J Curr Glaucoma Pract 2024;18(4):147-154.</p>","PeriodicalId":15419,"journal":{"name":"Journal of Current Glaucoma Practice","volume":"18 4","pages":"147-154"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915359/pdf/","citationCount":"0","resultStr":"{\"title\":\"Outcomes of MicroPulse<sup>®</sup> Transscleral Laser Therapy Using the Revised MicroPulse P3<sup>®</sup> Delivery Device.\",\"authors\":\"Maya Ramachandran, Jackson Voss, Jessica Ferrell, Jella Angela An\",\"doi\":\"10.5005/jp-journals-10078-1460\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims and background: </strong>To evaluate the safety and efficacy of MicroPulse<sup>®</sup> transscleral laser therapy (MP-TLT) using the revised MicroPulse P3<sup>®</sup> (MP3) probe compared to the original probe.</p><p><strong>Materials and methods: </strong>A retrospective study of 122 consecutive eyes of 99 glaucoma patients who received MP-TLT with a minimum of 12 months follow-up. The primary outcome was success at 12 months, defined as final IOP <18 mm Hg and either IOP reduction of >20% or any medication reduction, without any adverse events or secondary surgical interventions (SSIs) within 12 months.</p><p><strong>Results: </strong>Ninety-five eyes in 75 patients were treated with the original probe, and 27 eyes of 24 patients were treated with the revised probe. The mean total energy and fluence used were 113.6 joules (J) and 54.3 J/cm<sup>2</sup> for the original probe, and 79.9 J and 140.1 J/cm<sup>2</sup> for the revised probe. Subjects were mostly white with primary open-angle glaucoma and a mean age of 70.3 years. Significantly more eyes with advanced glaucoma were treated with the revised probe compared to the original probe (<i>p</i> < 0.001). At baseline, mean IOP was 23.0 ± 7.5 on 2.94 ± 1.19 medications for the original probe compared to 22.6 ± 6.9 (<i>p</i> = 0.799) on 3.15 ± 1.32 medications (<i>p</i> = 0.429) for the revised probe. At 12 months, mean IOP was 17.9 ± 5.9 mm Hg (21.4% reduction) on 2.55 ± 1.40 medications (13.0% reduction) for the original probe compared to 14.8 ± 5.7 mm Hg (29.7% reduction, <i>p</i> = 0.063) on 3.07 ± 1.49 medications (2.2% reduction, <i>p</i> = 0.279) for the revised probe. Thirty-one of 95 eyes (32.6%) and 11 of 27 eyes (40.7%) treated with original and revised MP-TLT, respectively, achieved success at 12 months (<i>p</i> = 0.435). The rate of SSIs was 12% and similar between groups (<i>p</i> = 0.833). Significantly more eyes treated with the original probe underwent repeat MP-TLT within 12 months (44.2 vs 22.2%, <i>p</i> = 0.049). No adverse events occurred in either group.</p><p><strong>Conclusion and clinical significance: </strong>The revised probe for the MP3 device may result in an improved and longer-lasting IOP-lowering effect compared to the original probe, while maintaining an excellent safety profile.</p><p><strong>How to cite this article: </strong>Ramachandran M, Voss J, Ferrell J, <i>et al</i>. Outcomes of MicroPulse<sup>®</sup> Transscleral Laser Therapy Using the Revised MicroPulse P3<sup>®</sup> Delivery Device. J Curr Glaucoma Pract 2024;18(4):147-154.</p>\",\"PeriodicalId\":15419,\"journal\":{\"name\":\"Journal of Current Glaucoma Practice\",\"volume\":\"18 4\",\"pages\":\"147-154\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915359/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Current Glaucoma Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5005/jp-journals-10078-1460\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Current Glaucoma Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5005/jp-journals-10078-1460","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
目的与背景：评价改良后的MicroPulse P3 （MP3）探针在经巩膜激光治疗（MP-TLT）中的安全性和有效性。材料与方法：回顾性研究99例接受MP-TLT治疗的青光眼患者122只连续眼，随访至少12个月。主要终点是12个月时的成功，定义为最终IOP 20%或任何药物降低，12个月内无任何不良事件或二次手术干预（ssi）。结果：75例患者95只眼使用了原探头，24例患者27只眼使用了改良探头。原始探针的平均总能量和通量为113.6焦耳(J)和54.3 J/cm2，改进探针的平均总能量和通量为79.9 J和140.1 J/cm2。受试者多为白人，原发开角型青光眼，平均年龄70.3岁。与原始探针相比，改良探针治疗晚期青光眼的眼睛数量明显增加（p < 0.001）。基线时，原始探头在2.94±1.19种药物治疗时的平均IOP为23.0±7.5，而改良探头在3.15±1.32种药物治疗时的平均IOP为22.6±6.9 （p = 0.799）。12个月时，使用原始探头治疗2.55±1.40种药物（降低13.0%）的平均IOP为17.9±5.9 mm Hg（降低21.4%），而使用改良探头治疗3.07±1.49种药物（降低2.2%,p = 0.279）的平均IOP为14.8±5.7 mm Hg（降低29.7%,p = 0.063）。原MP-TLT治疗的95只眼中有31只（32.6%），27只眼中有11只（40.7%）在12个月时取得了成功（p = 0.435）。ssi发生率为12%，组间差异无统计学意义（p = 0.833）。使用原始探针治疗的眼睛在12个月内重复MP-TLT的数量明显增加（44.2 vs 22.2%, p = 0.049）。两组均未发生不良事件。结论及临床意义：改良后的MP3设备探头与原始探头相比，在保持良好安全性的同时，可获得更好且更持久的降血压效果。本文引用方式：Ramachandran M， Voss J, Ferrell J，等。MicroPulse®经巩膜激光治疗使用改进的MicroPulse P3®传送装置的结果中华青光眼杂志；2009;18(4):147-154。
Outcomes of MicroPulse® Transscleral Laser Therapy Using the Revised MicroPulse P3® Delivery Device.
Aims and background: To evaluate the safety and efficacy of MicroPulse® transscleral laser therapy (MP-TLT) using the revised MicroPulse P3® (MP3) probe compared to the original probe.
Materials and methods: A retrospective study of 122 consecutive eyes of 99 glaucoma patients who received MP-TLT with a minimum of 12 months follow-up. The primary outcome was success at 12 months, defined as final IOP <18 mm Hg and either IOP reduction of >20% or any medication reduction, without any adverse events or secondary surgical interventions (SSIs) within 12 months.
Results: Ninety-five eyes in 75 patients were treated with the original probe, and 27 eyes of 24 patients were treated with the revised probe. The mean total energy and fluence used were 113.6 joules (J) and 54.3 J/cm2 for the original probe, and 79.9 J and 140.1 J/cm2 for the revised probe. Subjects were mostly white with primary open-angle glaucoma and a mean age of 70.3 years. Significantly more eyes with advanced glaucoma were treated with the revised probe compared to the original probe (p < 0.001). At baseline, mean IOP was 23.0 ± 7.5 on 2.94 ± 1.19 medications for the original probe compared to 22.6 ± 6.9 (p = 0.799) on 3.15 ± 1.32 medications (p = 0.429) for the revised probe. At 12 months, mean IOP was 17.9 ± 5.9 mm Hg (21.4% reduction) on 2.55 ± 1.40 medications (13.0% reduction) for the original probe compared to 14.8 ± 5.7 mm Hg (29.7% reduction, p = 0.063) on 3.07 ± 1.49 medications (2.2% reduction, p = 0.279) for the revised probe. Thirty-one of 95 eyes (32.6%) and 11 of 27 eyes (40.7%) treated with original and revised MP-TLT, respectively, achieved success at 12 months (p = 0.435). The rate of SSIs was 12% and similar between groups (p = 0.833). Significantly more eyes treated with the original probe underwent repeat MP-TLT within 12 months (44.2 vs 22.2%, p = 0.049). No adverse events occurred in either group.
Conclusion and clinical significance: The revised probe for the MP3 device may result in an improved and longer-lasting IOP-lowering effect compared to the original probe, while maintaining an excellent safety profile.
How to cite this article: Ramachandran M, Voss J, Ferrell J, et al. Outcomes of MicroPulse® Transscleral Laser Therapy Using the Revised MicroPulse P3® Delivery Device. J Curr Glaucoma Pract 2024;18(4):147-154.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
